UPDATE: UBS Upgrades Eli Lilly (LLY) to Buy, New Top Pick
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Eli Lilly & Co. (LLY) the 'Most Attractive Name' in UBS Large Cap Coverage
September 22, 2022 11:35 AM EDTUBS analyst Colin Bristow raised Eli Lilly's (NYSE: LLY) rating to Buy from Neutral, with its price target raised to $363 per share from $335.
Bristow explained, in a research note, they have been on the sidelines with LLY, primarily due to concerns around the risk-reward into... More
